Industry veteran brings over 30 years of experience driving technical, operational, and commercial excellence
ElevateBio, a technology-driven company focused on powering the creation of life-transforming genetic medicines, announced the appointment of Ger Brophy, Ph.D., as Interim Chief Executive Officer and a member of the Board of Directors, effective. Dr. Brophy succeeds David Hallal, who transitioned to Executive Chairman of the Board as previously announced.
Dr. Brophy has served as a strategic advisor to ElevateBio’s leadership team since May 2024, focused on enterprise-wide growth and expansion opportunities across BaseCamp, ElevateBio’s end-to-end genetic medicine process development and cGMP manufacturing business, and Life Edit, its gene editing and R&D technology business. His advisory work had included expanding the Company’s manufacturing capabilities, enhancing operational effectiveness, and establishing scalable organizational structures to support ElevateBio’s long-term vision.
“We are fortunate to have someone of Ger’s caliber leading ElevateBio over the next year,” said David Hallal, Executive Chairman of ElevateBio. “His vast experience in the life sciences industry and deep understanding of our business gained through his advisory role, combined with his impressive track record of growing businesses and scaling operations, position him well to advance our genetic medicines capabilities.”
Health Technology Insights: Verifyle, NBHAP Partner to Secure Patient Data
Prior to his advisory role at ElevateBio, Dr. Brophy served as Executive Vice President of BioPharma Production at Avantor, where he continues to serve as the Chair of the Scientific Advisory Board. At Avantor, he led commercial, R&D, production, quality, and regulatory activities and expanded bioproduction capabilities and geographic footprint, increasing revenue and productivity. Before Avantor, he was Head of Cell Therapy at GE Healthcare Life Sciences, where he built and led the newly formed cell therapy manufacturing business. Dr. Brophy also served as Chief Technology Officer of GE Healthcare Life Sciences, where he was responsible for the R&D portfolio and developed an integrated R&D strategy across five newly merged business segments – experience that uniquely positions him to oversee both ElevateBio’s BaseCamp and Life Edit businesses.
Health Technology Insights: Kouper Launches with $10Million to Improve Care Transitions
“I am honored to take on the role of Interim CEO at ElevateBio as we continue to differentiate ourselves through industry-leading expertise and technologies. Our commitment is to support our partners to access and produce new breakthroughs in genetic medicine,” said Dr. Ger Brophy. “Having worked closely with the leadership team over the past year, I’ve gained a deep appreciation for our integrated approach that unites manufacturing and gene editing capabilities. I’m committed to building on the strong foundation that David and the team have created and to further strengthening our position as the industry leader in powering the next generation of genetic medicines.”
Health Technology Insights: Sirius Therapeutics Raises $50Million for siRNA Drug Development
To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com
Source – GlobeNewswire
